Adds details throughout
Dec 11 (Reuters) - Candel Therapeutics CADL.O said on Wednesday its experimental immunotherapy for prostate cancer met the main goal of a late-stage trial, helping the company's shares more than double in value in premarket trading.
The immunotherapy, CAN-2409, in combination with radiation therapy significantly improved disease-free survival in patients, compared to radiation alone, the company said.
Candel said it plans to discuss with the Food and Drug Administration regarding the therapy in intermediate-to-high-risk localized prostate cancer.
Over 100,000 men are diagnosed with prostate cancer every year in the U.S., the company said.
The company's shares were up 176.8% at $12.76 in trading before the bell.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。